

**Supplementary Table 2.** Baseline clinical and biochemical characteristics according to age group

Age group	<53 Years	≥53 Years	P value
Number	152	171	
Age, yr	44.6±6.5	60.2±5.3	<0.0001
Male sex, %	52.6	55.0	0.6738
Nationality (Indian/Korean), %	40.1/59.9	20.5/79.5	0.0001
Body mass index, kg/m <sup>2</sup>	26.391±3.613	25.329±3.298	0.0013
Waist circumference, cm	90.48±9.47	88.55±8.69	0.0573
Duration of T2DM, yr	4.245±3.382	7.830±5.266	<0.0001
DPP-4 inhibitor (sitagliptin/gemigliptin), %	30.3/69.7	32.7/67.3	0.6315
HbA1c at baseline, %	8.136±0.797	7.905±0.782	0.0023
FPG at baseline, mg/dL	151.809±35.226	138.421±24.228	0.0002
Total cholesterol at baseline, mg/dL	170.020±41.886	164.076±35.700	0.2277
HDL-C at baseline, mg/dL	40.888±11.459	46.485±11.958	<0.0001
LDL-C at baseline, mg/dL	92.553±32.744	91.380±30.253	0.4992
TG at baseline, mg/dL	186.072±143.187	139.754±95.223	<0.0001
HOMA-IR at baseline	4.322±5.863	3.208±1.736	<0.0001
HOMA-β at baseline	53.129±42.467	46.939±23.154	0.8974
Baseline DPP-4 activity	22.334±5.197	22.529±4.470	0.7169
HbA1c difference from baseline to week 24, %	-0.757±0.787	-0.998±0.724	0.0011
DPP-4 inhibition rate at week 24, %	64.03±18.64	70.85±16.47	<0.0001

Values are presented as mean ± standard deviation.

T2DM, type 2 diabetes mellitus; DPP-4, dipeptidyl peptidase-4; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function.